Simpson, Richard W

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.

Del Prato, S., Kahn, S. E., Pavo, I., Weerakkody, G. J., Yang, Z., Doupis, J., Aizenberg, D., Wynne, A. G., Riesmeyer, J. S., Heine, R. J., et al. (2021) · The Lancet

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 684

A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules

Liu, H., Dear, A. E., Knudsen, L. B., & Simpson, R. W. (2009) · Journal of Endocrinology

Diabetes Treatment and ManagementAdipokines, Inflammation, and Metabolic Diseases

Cited by 187

The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE −/− mouse model

Gaspari, T., Welungoda, I., Widdop, R. E., Simpson, R. W., & Dear, A. E. (2013) · Diabetes and Vascular Disease Research

Diabetes Treatment and ManagementAtherosclerosis and Cardiovascular Diseases

Cited by 148

The efficacy of IDegLira (insulin degludec/liraglutide combination) in adults with type 2 diabetes inadequately controlled with a GLP-1 receptor agonist and oral therapy: DUAL III randomized clinical trial

Linjawi, S., Bode, B. W., Chaykin, L. B., Courrèges, J.-P., Handelsman, Y., Lehmann, L. M., Mishra, A., & Simpson, R. W. (2017) · Diabetes Therapy

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 136

Prospective clinical trial of hepatitis b vaccination in adults with and without type-2 diabetes mellitus

Van Der Meeren, O., Peterson, J. T., Dionne, M., Beasley, R., Ebeling, P. R., Ferguson, M., Nissen, M. D., Rheault, P., Simpson, R. W., De Ridder, M., et al. (2016) · Human Vaccines & Immunotherapeutics

Hepatitis B Virus StudiesIntramuscular injections and effects

Cited by 34